Stryker (SYK) Q2 FY26 earnings call: guidance and Q&A

Why was guidance narrowed, especially lowering the top end? How should H2 revenue growth be viewed? Why isn't the Q2 EPS beat fully flowing through to full-year guidance?

The narrowed guidance reflects current visibility and the remaining work for the year, with confidence in the 8.3-9.3% range. The Q2 EPS beat was partially due to tariff refunds, but full-year guidance is offset by ongoing costs from the Q1 cyber event, including lost manufacturing absorption and IT remediation expenses. H2 growth depends on production ramp and new product launches.

“So from an EPS standpoint, when we look at the beat in the quarter, it is driven partially by the tariff refunds that are happening that happened in the quarter. But as a reminder, when we talked about the first quarter earnings, and those were obviously well below expectations driven by the cyber event. There are costs that are coming through from a cyber perspective, both lost absorption from manufacturing as well as our IT costs that we have that we're planning for as we come through the remediation that will offset that benefit.”

asked by Joanne Wuensch · answered by Preston Wells

How much of Q2's performance was due to underlying business momentum versus catch-up from Q1's cyber event? Can any quantification be provided?

Q2 primarily reflects underlying business momentum, with strong demand for capital products. A significant uptick from capital is expected in H2 due to production ramps. While Peripheral Vascular faced an unexpected disruption, other areas like Endoscopy and Medical outperformed, contributing to the overall performance.

“I mean there are some areas that, that was a little bit easier where there's just some catch-up revenue to book. I would say, for the most part, what we are seeing is we are seeing continued momentum across all of our businesses we see really strong demand for our capital products. Like that's the one where we'll see a more significant uptick. In the second half of the year, based on what Kevin talked about earlier with production ramping and really getting ourselves back online to be able to produce at a faster rate to support the volumes that we have.”

asked by Robert Marcus · answered by Preston Wells

What drives confidence in achieving approximately 11% organic growth in H2 to reach the midpoint of guidance, especially with vascular issues? Why is more catch-up expected in H2 than Q2?

Confidence is high due to tremendous orders for capital equipment and clear visibility into the production ramp. The decision to raise the lower end of the sales guidance (from 8% to 8.3%) reflects this. Catch-up will occur steadily across both Q3 and Q4, driven by the ability to manufacture and ship products for which orders already exist.

“Listen, we lowered the bottom end of our range. That should give you some idea. We're not going to lower the bottom end of our -- sorry, base the bottom end of our sales guidance from 8% to 3%, right? So if you're raising that, that means you really don't see a risk of us being able to deliver at the lower end. And that raising is based on just tremendous orders for our capital.”

asked by Larry Biegelsen · answered by Kevin Lobo

Can you elaborate on the H2 margin and EPS cadence, especially given assumptions of lower Q4 EPS? Are there additional expenses or margin impacts from excess production?

Stryker remains committed to 150 basis points of operating margin expansion over three years. H2 EPS will be impacted by several factors, including lost absorption and IT remediation costs from the Q1 cyber event, and pressures from raw materials. These are partially offset by tariff refunds. Managing these macro items will determine the H2 cadence, with aggressive focus on efficiency.

“We do have this year several larger moving parts. So obviously, with the cyber event, we have manufacturing shutdown for some period of time and say you lost absorption idle costs that are sitting there that we have to recover from. We also have a lot of work ahead of us in terms of the remediation and stabilization from a cybersecurity perspective. So there's money that's going to be spent throughout the year to support those two activities that are really related to the cyber event itself.”

asked by Ryan Zimmerman · answered by Preston Wells

Given the stock price and strong cash flow, is there a bias towards share repurchases? What is the potential size of the share repurchase program?

M&A remains the number one capital allocation priority. However, strong cash flow generation allows for opportunistic share buybacks. The Board has previously approved approximately $1 billion for repurchases. The actual size and timing will depend on deal flow and the current valuation of Stryker's shares.

“In terms of size and what that could look like, we do have already approved from a prior approval by the Board about $1 billion available for us. I'm not saying that's what we're going to do, but that's what we have available. And it's something that we are going to take a look at. It's going to really depend on deal flow and timing of that deal flow from an M&A standpoint as well as what the current valuation is of our share.”

asked by Vijay Kumar · answered by Preston Wells

What is the current state and underlying trajectory of the mechanical thrombectomy market? What is a sustainable growth rate, and could it accelerate? How will IVL be positioned for cross-selling?

The mechanical thrombectomy market has huge growth potential, with the Peerless 2 study readout (mid-next year) expected to be a major catalyst. New competitors are mainly in aspiration, while Stryker offers a full product suite. The IVL product for above-the-knee peripheral vascular is submitted for approval with potential sales by year-end, and a coronary indication trial is underway. Stryker will continue to broaden technologies in this call point.

“The equivalent of that is a peerless 2 study that we just finished enrolling patients just finished enrolling. It takes roughly a year to do the data readout on all the processing and everything. So that will come out kind of mid-next year. And I think that will lift the entire market because of the -- it's really a high-powered, very, very important clinical trial.”

asked by Mathew Blackman · answered by Kevin Lobo